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Abstract: Retroviruses cause cancers in a variety of animals and humans. Research on 
retroviruses has provided important insights into mechanisms of oncogenesis in humans, 
including the discovery of viral oncogenes and cellular proto-oncogenes. The subject of 
this review is the mechanisms by which retroviruses that do not carry oncogenes   
(non-acute retroviruses) cause cancers. The common theme is that these tumors result from 
insertional activation of cellular proto-oncogenes by integration of viral DNA. Early 
research on insertional activation of proto-oncogenes in virus-induced tumors is reviewed. 
Research on non-acute retroviruses has led to the discovery of new proto-oncogenes 
through searches for common insertion sites (CISs) in virus-induced tumors. Cooperation 
between different proto-oncogenes in development of tumors has been elucidated through 
the study of retrovirus-induced tumors, and retroviral infection of genetically susceptible 
mice (retroviral tagging) has been used to identify cellular proto-oncogenes active in 
specific oncogenic pathways. The pace of proto-oncogene discovery has been accelerated 
by technical advances including PCR cloning of viral integration sites, the availability of 
the mouse genome sequence, and high throughput DNA sequencing. Insertional activation 
has proven to be a significant risk in gene therapy trials to correct genetic defects with 
retroviral vectors. Studies on non-acute retroviral oncogenesis provide insight into the 
potential risks, and the mechanisms of oncogenesis.  
Keywords: retrovirus; proto-oncogene; oncogenesis; retroviral vector; oncogene; non-
acute retrovirus; gene therapy 
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1. Introduction 
Retroviruses have historically been of interest because they induce cancers in animals; some of the 
fundamental principles of molecular cancer biology were first discovered through studies on these 
viruses (e.g., the discovery of oncogenes and proto-oncogenes). Retroviruses of humans are associated 
with human T-cell leukemia (HTLV-I) and AIDS (HIV-1). Very recently new human retroviruses have 
been discovered (e.g., XMRV) [1,2], and their relationships to human disease are under debate and 
active investigation [1,3–10]. This review will focus on non-acute retroviruses—those that induce 
tumors indirectly through activation of cellular genes.  
2. Retrovirus Structure and Replication 
Retroviruses have been studied intensively for the past forty years, and many details of their 
structure and replication have been elucidated (reviewed in Coffin et al. [11]). A brief summary is 
provided here. Retroviruses are enveloped RNA viruses that carry two identical copies of genomic 
RNA in the virion. They have relatively simple genomes (8–12 Kb in length); the genomic RNA is 
positive stranded and resembles cellular mRNA in that is capped at the 5' end and polyadenylated at 
the 3' end. All retroviruses contain at least three genes: gag that encodes the viral core proteins (matrix 
[MA], capsid [CA] and nucleocapsid [NC]), pol that encodes the viral enzymes (protease [PR], reverse 
transcriptase [RT] and integrase [IN]), and env that encodes the proteins of the viral envelope (surface 
[SU] and transmembrane [TM]). The retrovirus life cycle is illustrated in Figure 1. When retroviruses 
infect cells, they bind to cell surface receptors via the envelope SU protein. The bound virus then 
enters the cell either by receptor-mediated endocytosis or fusion at the plasma membrane. The result is 
viral cores in the cytoplasm. Reverse transcriptase is activated within the cores, where it uses the viral 
RNA as a template for synthesis of linear double-stranded viral DNA. The viral DNA is then 
transported to the nucleus, where it is integrated into the host chromosome by the viral integrase, to 
form the provirus. Integration of viral DNA into the host DNA occurs at multiple (almost random) 
sites, although for various retroviruses there is some preference for integration. For instance, murine 
leukemia viruses tend to favor viral DNA integration near transcriptional start sites [12]. The provirus 
is transcribed by cellular RNA polymerase II, yielding a viral transcript that is identical to genomic 
RNA. The viral transcript is exported to the cytoplasm with or without mRNA splicing. In the 
cytoplasm, spliced viral mRNA is translated into a polyprotein precursor for envelope protein. Some of 
the cytoplasmic unspliced viral RNA is translated into precursor polyproteins for Gag or Pol (a Gag or 
Gag-Pol polypeptide). The viral polyproteins combine with viral RNA to form virus particles that bud 
from the cell surface. The initially released viral particles are immature and non-infectious. Maturation 
results from viral protease cleavage of the viral polyproteins in released virions. Retroviral infection is 
typically not lytic—the end result of infection is a cell stably producing virus particles.  Viruses 2011, 3                  
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Figure 1. The retrovirus life cycle. See text for details. 
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The process of reverse transcription results in a viral DNA that is somewhat longer than the 
template viral RNA, due to the presence of long terminal repeats (LTRs) at either end of the viral DNA 
(Figure 2). The LTRs are subdivided into three regions, according to the region of the viral genome 
from where they are encoded. U3 sequences are encoded in viral RNA sequences Uniquely at the 3' 
end of the genome, U5 sequences are encoded from sequences Uniquely at the 5' end of the genome, 
and R sequences are encoded by RNA sequences that are Repeated at either end of the genome. The 
LTRs carry important transcriptional signals. These include a cleavage/polyadenylation site in the R 
region and a basal promoter and enhancers in U3. Transcription is initiated at the U3-R boundary in 
the upstream LTR, and cleavage/ polyadenylation takes place at the R-U5 boundary in the 
downstream LTR.  
Figure 2. Retroviral LTRs. The relationship of retroviral RNA to the reverse transcribed 
DNA is shown. The viral RNA contains short direct repeats at either end (R), and the viral 
DNA contains long terminal repeats. Subdivision of the LTR into U3, R and U5 regions is 
shown at the bottom. 
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3. Retroviral Oncogenesis: Acute Transforming vs. Non-Acute Retroviruses 
Retroviruses cause a variety of tumors in animals and humans, ranging from solid tumors such as 
carcinomas and sarcomas through hematopoietic neoplasms such as leukemias and lymphomas. They 
can be divided into two classes: acute transforming retroviruses and non-acute retroviruses [13]. As 
the name implies, acute transforming retroviruses induce tumors rapidly, while non-acute retroviruses 
induce tumors with a longer latency. Acute transforming retroviruses were among the first retroviruses 
to be discovered—Rous sarcoma virus (RSV), a virus that causes fibrosarcomas in chickens, is the 
prototypical virus of this class. A common feature of acute transforming retroviruses is that they carry 
additional genetic information—viral oncogenes [13,14]. The viral oncogenes endow acute 
transforming retroviruses with the ability to induce tumors rapidly, and acute transforming retroviruses 
frequently can alter the growth properties of infected cells in tissue culture (cell transformation) [15]. 
The oncogene of RSV is called v-src; it encodes a tyrosine-specific protein kinase [16–19]. Other acute 
transforming retroviruses carry different oncogenes; for instance avian MC29 virus that induces acute 
myeloid tumors in chickens carries an oncogene called v-myc [20] and avian erythroblastosis virus 
carries two oncogenes, v-erbA  and  v-erbB  [21]. Approximately 25 viral oncogenes have been 
discovered; in some cases more than one acute transforming retrovirus carries the same or a 
similar oncogene.  
A seminal finding was that retroviral oncogenes are actually derived from normal cell genes [22]. 
The normal cell counterparts of retroviral oncogenes are called cellular proto-oncogenes. For instance 
v-src was derived from the proto-oncogene c-src. As a group the cellular proto-oncogenes encode 
proteins that function in positive (but regulated) stimulation of cell growth or division and can promote 
cell survival. Viral oncogene proteins differ from the corresponding cellular proto-oncogene proteins 
in various ways, but a common theme is that the viral oncogene proteins cause unregulated stimulation 
of cell growth/division compared to their cellular proto-oncogene protein counterparts. Many cellular 
proteins in key signal transduction pathways were first discovered as cellular proto-oncogene 
counterparts of viral oncogenes. These include the cellular Ras [23–25], Raf [26,27], Myc [28,29], Fos 
[30,31], Jun [32,33], and Akt [34,35] proteins to name a few. The discovery of cellular proto-oncogenes 
was of fundamental importance to cancer research, since it became apparent that non-viral cancers 
frequently have activating mutations of proto-oncogenes [36,37] or they over-express them through 
gene amplification [38–40] or chromosomal translocation [41–43]. These were the first kinds of 
genetic mutations in human cancers to be identified.  
Non-acute retroviruses do not carry viral oncogenes, and they do not transform cells in culture. 
They induce tumors more slowly than acute transforming retroviruses. Non-acute retroviruses have the 
standard genome organization of retroviruses, while most acute-transforming retroviruses are 
replication-defective because they have substituted oncogene sequences in place of viral genes. These 
viruses must be co-infected with a related “helper virus” that provides the viral structural proteins to 
make infectious particles. Examples of non-acute retroviruses include avian leukosis viruses that 
induce lymphoid tumors in chickens, murine leukemia viruses (MuLVs) that induce leukemias, murine 
mammary tumor virus (MMTV) that induces mammary carcinomas, and feline leukemia viruses 
(FeLVs) [13]. The mechanisms by which these non-acute retroviruses induce tumors will be subject of 
this review.  Viruses 2011, 3                  
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4. Insertional Activation of Proto-Oncogenes 
The landmark study that elucidated the basic principle of how non-acute retroviruses induce tumors 
was published by Hayward et al. in 1981 [44]. These investigators studied B-lymphomas in chickens 
induced by avian leukosis virus (ALV). They carried out Southern blot and Northern blot analyses of 
multiple ALV-induced tumors using two hybridization probes for ALV: a probe representative of the 
entire ALV genome (cDNArep) and another one that contained sequences only from the 5' end (the R 
and U5 regions of the LTR-cDNA5'). Analysis of Southern blots of tumor DNAs with the ALV 
cDNArep probe indicated that while viral DNA could be detected in all tumors, there were frequently 
missing viral sequences. Likewise when tumor RNAs were studied by Northern blotting with cDNArep, 
not all tumors showed evidence for viral RNA transcripts. On the other hand, all of the tumors showed 
transcripts that could be detected by ALV cDNA5'. The fact that the transcripts could be detected by 
cDNA5' but not cDNArep led Hayward et al. to propose that they represented transcripts that initiated in 
the downstream LTR and read into adjacent host sequences [44]. Moreover, the fact that the transcripts 
detectable by cDNA5' from the different tumors were of approximately the same size led the 
investigators to propose that viral DNA was being inserted into the same chromosomal locations in the 
different tumors—the length of the transcripts would be determined by the site of proviral insertion 
and the relative position of the cleavage/polyadenylation signals in the host cell DNA. They proposed 
that the inserted proviral DNA was leading to over-expression of the host cellular gene by   
read-through transcription from the viral LTR, a process termed “promoter insertion” (Figure 3A). 
Over-expression of the cellular gene was ultimately responsible for the leukemogenesis.  
Proof of the promoter insertion model for ALV leukemogenesis was obtained when the activated 
cellular gene was identified. Hayward et al. tested the hypothesis that the activated cellular gene might 
be a proto-oncogene, i.e., the cellular homolog of a known viral oncogene [44]. They were able to 
demonstrate that these tumors contained ALV DNA inserted next to the c-myc proto-oncogene. This 
was accomplished by using a v-myc hybridization probe that would cross-hybridize with c-myc 
sequences. They showed that the RNA transcripts in ALV-induced tumors that could hybridize with 
cDNA5' would also hybridize with the v-myc hybridization probe, and that the c-myc genes in the 
tumors also had insertions of ALV DNA.  
The promoter insertion mechanism of ALV leukemogenesis also provided a conceptual framework 
for understanding the relatively long latency of the disease. Since retroviruses integrate proviral DNA 
at virtually random sites throughout the genome, the likelihood of an insertion in the vicinity of c-myc 
in any infected cell would be quite low. Multiple rounds of infection (and time) would be necessary 
before an ALV provirus inserted next to c-myc in one infected cell. That infected cell would then 
receive the enhanced growth signals and develop into the tumor. For this reason, tumors induced by 
non-acute retroviruses are also typically monoclonal or oligoclonal outgrowths of a single (or small 
number) of infected cells. However, as discussed below, the long latency of disease is affected by other 
factors as well.  
The studies of Hayward et al. [44] were followed up by another group in which ALV-induced  
B-lymphomas induced in chickens with a different genetic background were examined [45]. They 
confirmed integration of ALV proviruses adjacent to c-myc in tumor DNAs, as well as the   
over-expression of c-myc RNA. However, not all of the tumors had proviral integrations compatible Viruses 2011, 3                  
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with promoter insertion activation of c-myc (Figure 3B). In some cases the ALV provirus was inserted 
upstream of c-myc but in the opposite transcriptional orientation, or downstream from c-myc but in the 
same orientation. These cases ultimately have been ascribed to the strong ALV enhancers in the LTR 
activating the endogenous c-myc promoter, resulting in over-expression of a normal c-myc transcript. 
T-lymphomas induced in mice by Moloney murine leukemia virus (M-MuLV) have also been found to 
result from activation of c-myc  [46,47], and in this case the predominant mechanism is enhancer 
activation [46]. In addition, other M-MuLV-induced T-lymphomas result from activation of novel 
proto-oncogenes (see following section).  
Figure 3. Insertion activation of c-myc  in avian leukosis virus (ALV)-induced   
B-lymphomas. (A) Promoter insertion activation of c-myc as reported by Hayward et al. [42]. 
(B) Enhancer activation of c-myc (one of the configurations) reported by Payne et al. [43].  
ALV provirus c-myc
A.  PROMOTER INSERTION
ALV provirus c-myc
B.  ENHANCER ACTIVATION
 
 
Another group studied tumors induced by ALV, but in a line of chickens resistant to lymphoma, 
where erythroleukemias developed instead [48]. In this case, promoter insertion of a different   
proto-oncogene c-erbB (a.k.a. epidermal growth factor receptor) occurred. In these tumors proviral 
insertion was into the coding sequences of c-erbB, and transcription initiated in the upstream ALV 
LTR, with read-through from the downstream LTR into c-erbB [49,50]. This resulted in a fusion 
transcript that was further processed by mRNA splicing to encode a novel protein containing viral Gag 
and Env sequences fused to a truncated EGF receptor.  
Overall, the general mechanism for oncogenesis by non-acute retroviruses can be considered to be 
LTR-activation of proto-oncogenes. This includes classical promoter insertion as well as enhancer 
activation. Depending on the retrovirus and the biological system, one or the other, or both 
mechanisms may predominate.  Viruses 2011, 3                  
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5. Discovery of New Proto-Oncogenes by Studying Insertional Activation 
Other investigators studied tumors induced by other non-acute retroviruses using the same 
conceptual framework as developed by Hayward et al. However, in some cases many if not all of the 
tumors did not show proviral insertions in the vicinity of proto-oncogenes known at the time.   
Nusse et al. studied mammary tumors induced by MMTV in mice [51]. They identified tumors with 
relatively low numbers of inserted proviruses by Southern blotting, and then they cloned all of the 
proviruses from such a tumor. The adjacent cellular sequences from the different proviruses were then 
used as hybridization probes in Southern blots of other MMTV-induced tumors, in search of common 
insertion sites (CISs). It was hypothesized that a CIS would be in the vicinity of a cellular gene that 
was activated by proviral insertion. In any given tumor, all of the integrated proviruses would not 
necessarily represent a CIS; indeed only one or a small number would likely be. Hence the searches for 
CISs began with tumors containing small numbers of inserted proviruses, to increase the probability 
that any cloned provirus represented a CIS. In the case of MMTV-induced mammary tumors, the CISs 
were designated int-1 and int-2 [51–53], and subsequent studies of MMTV led to identification of int-3 
[54]. Int-1 is a founding member (Wnt1) of the Wnt family of growth factor receptors, which are 
components of the Wnt-beta-catenin signaling pathway [55]. This pathway is frequently dysregulated 
in many human epithelial tumors such as colon cancer [56]. Int-2 has been subsequently found to be 
the same as fibroblast growth factor 3 (Fgf3), and int-3 has been found to be Notch4 [55].  
Similar studies on various MuLV strains in mice and rats have led to identification of other novel 
proto-oncogenes through identification of CISs (Table 1). These include pim-1 [57], pim-2 [58], Mis-1 
[59], Spi-1 [60,61] and Fli-1 [62]. Pim-1 is a serine-threonine kinase, and Spi-1 (PU.1) and Fli-1 are 
transcription factors of the Ets family. In each of these cases, this was the first identification of these 
genes, which have subsequently been found to play important roles in normal physiology, and to be 
dysregulated in certain cancers. In addition to the CISs identified from tumors induced by exogenous 
retroviruses, Copeland, Jenkins and co-workers have employed recombinant inbred mouse strains that 
have high frequencies of leukemia due to spontaneous activation of endogenous MuLVs—this has led 
to identification of another set of CISs termed endogenous virus insertions (evi-1, 2, etc.) [63].  
In general, a given non-acute retrovirus will induce a specific type of tumor, or a restricted range of 
tumor types (e.g., T-lymphomas for M-MuLV, myeloid and erythroid leukemias for Friend MuLV). 
Correspondingly, the tumors induced by a particular virus will typically show activation of a limited 
number of proto-oncogenes. For instance, T-lymphomas induced by M-MuLV predominantly show 
activation of c-myc, pim-1 and/or pim-2 [46,58]. In contrast, erythroid leukemias induced by Friend 
MuLV predominantly show activations of fli-1 [62], and myeloid tumors in recombinant inbred mice 
show activations of evi-1 [64]. This may reflect the relative abilities of particular proto-oncogenes to 
contribute to malignancy in different cell types when they are over-expressed. The genetic background 
of the host also affects the pattern of insertional activation (discussed in Section 7). 
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Table 1. Common insertion sites (CIS) or activated proto-oncogenes in MuLV-induced tumors
1. 
VIRUS  DISEASE  CIS or PROTO-ONCOGENE 
Moloney MuLV  T-lymphoma   
   In  mice: 
c-myc, pim-1, pvt-1/mis-1/mlvi-1, lck, pim-2
a, 
n-myc
a, bmi-1
a, frat-1
a, pal-1/gfi-1
a 
   In  rats: 
c-myc, pvt-1/mis-1/mlvi-1, mlvi-2, mlvi-3, 
mlvi-4, dsi-1, lck, tpl-1/ets-1
a, tpl-2
a, gfi-1/pal-
1
a, gfi-2/IL-9R 
 Myeloid  leukemia  c-myb, mml-1 
AKR MuLV/Gross Virus; 
SL3-3 MuLV 
T-lymphoma  c-myc, gin-1, n-ras 
RadLV (Radiation leukemia 
virus) 
T-lymphoma  c-myc, pim-1, vin-1/cyclinD2, notch1, kis-1, 
kis-2 
Friend MuLV  Erythroleukemia  fli-1, fre-2 
 Myeloid  leukemia  fis-1, fim-1, evi-1/fim-3, c-fms/fim-2 
Endogenous MuLV (AKXD, 
BXH-2 recombinant inbred 
mice) 
Myeloid leukemia  evi-1/fim-3, evi-2, meis-1 and others
1 
 B-lymphoma  evi-3 and others
1
Abelson MuLV 
(contains v-abl oncogene) 
B-lymphoma  ahi-1, ahi-2 (M-MuLV helper inserted) 
Friend SSFV  
(SFFV gp52
c is an oncogene) 
Erythroleukemia  Spi-1, p53
b
1 Data from retroviral tagging of mice genetically predisposed to cancer (e.g., myc transgenic mice) 
are not included here. They can be found in the Mouse Retrovirus Tagged Cancer Gene (RTCG) 
database [65,66].  
a Insertions associated with tumor progression or that collaborate with other proto-oncogene 
activations; 
b Insertion at p53 inactivates its function; 
c gp52 oncogene is a deleted form of endogenous retroviral envelope protein. 
6. LTRs as Determinants of Disease Specificity 
Related retroviruses can differ in their abilities to induced tumors, as well as the kinds of tumors 
induced. Generation of molecular chimeras between related viruses identified the LTRs as primary 
pathogenic determinants. For instance, the LTR from an oncogenic MuLV (e.g., Gross MuLV) could 
confer leukemogenicity to a related weakly leukemogenic Akv-MuLV [67,68]. Likewise the LTR from 
Friend MuLV that induces erythroleukemia could convert M-MuLV from inducing T-lymphoma to 
erythroleukemia [69]. This was extended to show that just the enhancer elements in the U3 region of 
the LTRs were sufficient to switch the disease specificity [70]. The disease specificity of the Friend vs. 
Moloney LTRs was also correlated with the relative transcriptional activities of these LTRs in 
lymphoid  vs. erythroid/myeloid cells [71]. Enhancer sequences consist of binding motifs for   Viruses 2011, 3                  
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sequence-specific transcription factors. For some retroviruses, these are tandemly repeated which 
makes binding stronger. 
The importance of the LTRs in oncogenicity of non-acute retroviruses can be understood in the 
context of LTR-activation of proto-oncogenes. In order for a non-acute retrovirus to induce oncogenic 
transformation of a particular differentiated cell, it must have an LTR that can transcriptionally activate 
proto-oncogenes in that cell (either by promoter insertion or enhancer activation). The enhancer 
sequences of the LTR bind cellular transcription factors, and they are frequently cell-specific, with 
binding motifs for factors that may be highly expressed in particular differentiated cells. Thus the 
ability of a retrovirus to activate proto-oncogenes and induce tumors will depend on the relative 
strength of the enhancer sequences, and the cells in which they are active.  
7. Cooperation among Activated Proto-Oncogenes 
In some cases tumors induced by non-acute retroviruses have shown evidence for activation of 
more than one proto-oncogene in the same tumor—e.g., int-1 (Wnt-1) and int-2 in MMTV-induced 
mammary tumors [72] and pim-1 and c-myc in M-MuLV-induced tumors [46]. This could reflect 
cooperation of the two proto-oncogenes (either within the same tumor cell or between adjacent cells), 
or simply two independent tumors in the same mass. This has been addressed by transplanting the 
original tumors into recipient animals and analyzing the secondary tumors for the presence (or not) of 
both proto-oncogene activations [72,73]. The results indicated that the tumors induced by these viruses 
are generally oligonal collections of independent tumors, some of which contain activation of one 
proto-oncogene while others contain activation of the other. On the other hand, in the case of   
MMTV-induced tumors with int-1 and int-2 insertions, transplantation into recipient mice resulted in 
maintenance of independent oligoclonal populations with int-1 and int-2 insertions when the tumors 
were hormone-dependent [72]. This suggests that in MMTV-induced hormone-dependent tumors, 
cooperation between tumor cell sub-populations with activated int-1 and int-2 genes may be occurring.  
Intracellular cooperation among proto-oncogenes in MuLV leukemogenesis was demonstrated by 
Berns and co-workers in transgenic mice over-expressing pim-1 under control of the immunoglobulin 
heavy chain enhancer (E) [74]. The transgenic mice developed T-cell lymphomas slowly (7 months) 
and at a low frequency (5–10%). However, when these mice were infected with M-MuLV all of them 
developed tumors and much more rapidly (7–8 weeks). The resulting tumors were found to harbor  
M-MuLV insertions near c-myc or the related n-myc proto-oncogene [74]. This provided strong 
evidence for cooperation between pim-1 and myc family proto-oncogenes in development of   
T-lymphoma. Cooperation between pim-1 and myc proto-oncogenes was again observed when mice 
transgenic for c-myc driven by the E promoter/enhancer (E-myc) were infected with M-MuLV [75]. 
Acceleration of leukemogenesis (T- or B-lymphoma) occurred, and a substantial fraction of the tumors 
showed proviral insertions next to pim-1. Other tumors showed novel CISs [75], leading to the 
identification of new proto-oncogenes (e.g., bmi-1). This discovery process is now referred to as 
retroviral tagging.  
Retroviral tagging in double and triple transgenic mice has been used to identify proto-oncogenes 
active in particular pathways. For instance E-myc/Pim-1
-/- mice were infected with M-MuLV with the 
goal of identifying proto-oncogenes that could substitute for Pim-1 [76]; the predominant activated Viruses 2011, 3                  
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proto-oncogene was Pim-2, indicating that it cooperates with c-myc in the absence of Pim-1. This 
rationale was extended to studies in Emyc/Pim-1
-/-/Pim-2
-/- mice where Pim-3 was identified [77]. 
Retroviral tagging studies in transgenic mice over-expressing myc from other T-cell specific promoters 
have identified other cooperating proto-oncogenes, including Notch1 [78] and Runx2 [79,80]. More 
recently the same strategy has been used by others to identify genes that can collaborate with myc and 
Runx2 [81] or complement deficiencies in multiple cycling-dependent kinase inhibitors [82].  
Recently retroviral tagging has been extended to identifying potential cooperating proto-oncogenes 
in solid tumors [83]. Inactivations of the APC tumor suppressor protein are important for colon cancer 
development [56]. Mouse colon epithelial cells from mice containing an APC mutation (Min) were 
infected in vitro with the MSCV strain of MuLV. Infected cells from Min mice formed colonies in soft 
agar while those from wild-type APC did not. Colony formation in agar is one property associated with 
malignant transformation. CISs in the agar colonies identified several proteins that can apparently 
collaborate with mutated APC in transformation [83].  
8. Insertional Activation in Multi-Step Carcinogenesis and Tumor Progression 
It is now well-understood that cancer is a multi-step process, with multiple genetic and biochemical 
changes taking place within a developing tumor cell. While insertional activation of proto-oncogenes 
by non-acute retroviruses has traditionally been viewed as an initiating or early event in tumor 
development, it can also participate in later steps in tumorigenesis. One interesting case was studies on 
B-lymphomas induced by Abelson MuLV. Ab-MuLV is an acute transforming retrovirus whose 
replication-defective genome carries the v-abl oncogene. In order to efficiently infect mice and induce 
lymphomas Ab-MuLV must be co-infected with a helper MuLV—originally M-MuLV. However 
when a different helper MuLV was employed (from an endogenous MuLV), the rapid leukemogenicity 
of Ab-MuLV was lost [84]. Chimeras between the two helper MuLVs indicated that the M-MuLV 
LTR was necessary for Ab-MuLV leukemogenesis. This led Poirier et al. to test the hypothesis that the 
M-MuLV helper was activating proto-oncogenes that cooperated with the v-Abl protein to produce the 
tumors [85], and they indeed indentified a CIS (ahi-1) in some of the tumors. This suggested that the 
M-MuLV helper is cooperating with v-Abl oncogene protein in inducing the rapid B-lymphomas.  
M-MuLV insertions into ahi-1 typically are downstream of the last exon, but in some cases they 
generate C-terminal truncations of the putative protein [86].  
The ability of activated proto-oncogenes to participate in later steps in M-MuLV leukemogenesis 
has been studied by Tsichlis and co-workers. When M-MuLV-induced lymphomas from rats are 
cultured  in vitro, they tend to acquire additional copies of M-MuLV proviruses. Bear et al. [87] 
hypothesized that these could represent activation of “tumor progression loci”, and they discovered 
several CISs in the cultured cells (tpl-1, tpl-2) [87,88]. They found evidence for insertional activation 
of these loci in tumors as well. These same workers also investigated the possibility that MCF 
recombinant viruses that arise in MuLV-infected mice could also be contributing to leukemogenesis by 
insertional activation. In vitro infection of M-MuLV-induced tumor cells with MCF recombinants and 
culture in the absence of growth factors led selection of cells with viral integrations into new CISs  
(gfi-1, gfi-2) [89,90]. Gfi-1 encodes a novel DNA binding protein, while gfi-2 encodes the IL-9 
receptor. Thus activation of proto-oncogenes can participate in later stages of oncogenesis, Viruses 2011, 3                  
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downstream of other proto-oncogene activations, viral oncogenes, or potentially non-viral 
oncogenic events.  
While MuLVs do not morphologically transform cells in culture, Heard et al. [91] have observed 
multi-stage changes culminating in development of myeloid leukemia cells when long term bone 
marrow cell cultures were infected in vitro with F-MuLV. With continued passage, cells in the culture 
progressed through stages of (1) enhanced responsiveness to macrophage colony stimulating factor  
(M-CSF/CSF-1), (2) growth factor independence, and ultimately (3) acquisition of tumorigenicty. 
Tumors induced in this system showed two novel CISs, Fim-1 and Fim-2 [92]; Fim-2 was later found 
to be the structural gene for M-CSF [93]. 
9. Other Mechanisms of Insertional Oncogenesis 
The most common mechanism of oncogenesis by non-acute retroviruses is transcriptional activation 
of proto-oncogenes. However proviral insertions can have other effects that result in oncogenic stimuli. 
One example is in erythroleukemias induced by the Friend virus complex—an acute transforming 
retrovirus (SFFV) as well as a helper virus (F-MuLV). Erythroleukemia cell lines established from 
these tumors show inactivation of the p53 tumor suppressor gene due to insertion of an SFFV provirus 
[94,95]. In most of the cell lines, the normal p53 gene was also lost, resulting in lack of functional p53. 
Insertional inactivation of the NF-1 tumor suppressor gene has also been found in myeloid leukemias 
arising in BXH-2 recombinant inbred mice [96]—the CIS originally termed evi-2 was found to be in 
the NF-1 gene.  
Another example is myeloid tumors induced by M-MuLV in adult Balb/c mice primed with 
pristane. Pristane treatment results in inflammation and myeloid cell expansion. The resulting tumors 
show insertion of M-MuLV proviruses within the 3rd or 4th introns of the c-myb proto-oncogene in the 
same transcriptional orientation [97,98]. This leads to expression of a hybrid transcript initiated in the 
M-MuLV provirus with readthrough into the downstream c-myb sequences; mRNA splicing leads to a 
truncated c-myb mRNA and a c-myb protein lacking an N-terminal negative regulatory domain [97]. 
This results in a constitutively active c-myb protein (transcription factor), which contributes to 
development of the myeloid tumors. Thus proviral insertion can lead to alteration (truncation) of a 
proto-oncogene protein that results in oncogenic activation. Another interesting feature of this system 
is that administration of pristane, which elicits a strong macrophage response, is necessary for 
development of the myeloid tumors [99]. The pristane is inducing inflammation and mitogenesis in 
myeloid cells that presumably cooperates with the oncogenic effects of the truncated c-Myb protein. 
Indeed, the same M-MuLV insertions into c-myb can be detected in lymphoid tissue from other strains 
of mice inoculated as newborns in the absence of pristane, but the T-lymphomas that develop do not 
show  c-myb insertions [100]. Thus the truncated c-Myb requires additional mitogenic stimuli to 
manifest its oncogenic effect, and this protein may not be effective in lymphoid cells. In fact in 
erythroleukemias induced by ALV in chickens, the activated form of the EGF receptor (c-erbB) is 
truncated at the amino terminus (extracellular growth factor binding domain), similar to the activated 
v-erbB oncoprotein of avian erythroblastosis virus [49].  
Another very interesting mechanism of insertional activation is in chicks infected embryonically 
and then post-hatching with ALV. Some of these animals developed B-lymphomas that frequently Viruses 2011, 3                  
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contained proviral insertions at c-myc as well as a novel CIS designated bic-1  [101]. The ALV 
insertion enhanced expression of the bic-1 transcript, but at the time, the mechanism of action of bic-1 
was unclear, since it could not encode any protein. More recently, bic-1 has been found to be the 
precursor of miR-155, a microRNA (miRNA) whose over-expression has been observed in human 
cancers as well [102]. Over-expression of miR-155 leads to down-regulation of target transcripts—
tumor suppressors such as JARID2/jumonji [103]. Indeed, bic-1 is the first oncogenic miRNA to be 
discovered. Similarly a CIS previously identified in RadLV—induced T-lymphomas in mice (Kis2) 
has been found to encode the precursor for the miRNA cluster, miR-106-363 [104]. Over-expression 
of miR-106-363 could induce anchorage-independent growth, and human T-lymphomas also showed 
over-expression of this miRNA cluster [104]. In SL3-3 MuLV-induced T-lymphomas, proviral 
insertion and over-expression of the miR-106a cistron has also been reported [105].  
Another recent study has characterized T-lymphomas in mice induced by the SL3-3 strain of MuLV 
[106]. A frequent CIS in these tumors was found to be the Gfi-1 proto-oncogene (see above). 
Interestingly, in some cases, the proviral insertion was into the 3' untranslated region of the gfi-1 RNA, 
resulting in a truncated transcript. Tumors with such transcripts showed a high level of Gfi-1 protein, 
while tumors that did not have proviruses inserted in the 3' UTR did not. Dabrowska et al. provided 
evidence that the 3' UTR of Gfi-1 contains target sites for several miRNAs (including   
miR-155), and that the proviral insertions would uncouple the Gfi-1 coding sequences from the 
miRNA binding sites [106]. Thus over-expression of Gfi-1 protein could result from truncation of 
miRNA binding sites.  
10. Insertional Mutagenesis in the Age of Genomics 
Original methods to identify CISs were laborious and time consuming, involving Southern blotting, 
screening DNA libraries, genome walking and extensive cloning. Due to the large distances over 
which a provirus can act on a gene and the limited knowledge of the mouse genome, identification of the 
proto-oncogenes in the vicinity of a CIS was challenging. Identification of CISs and retroviral tagging 
drastically changed with the development of PCR-based strategies (inverse and splinkerette-based PCR) 
for cloning host-virus junctions, along with sequencing of the mouse genome. The host DNA on 
cloned host-virus junction fragments could be aligned with the mouse genome, yielding precise 
location of the insertions sites. Thus high-throughput studies could be performed with hundreds of 
insertion sites identified in a single study. Copeland and co-workers were the first to use this approach 
on leukemias arising in recombinant inbred mice (AKXD and BXH-2), identifying more than 90 
potential CISs in one experiment [107]. Other investigators have carried out similar studies, using 
retroviral tagging in wild-type or in tumor-prone transgenic/knock-out mice. This allowed 
identification of novel CISs involved in development of particular tumor types, or that collaborate with 
known oncogenic pathways [77,81,108–110]. Currently, over 600 CISs have been identified. For a 
compilation of these sites see the Mouse Retrovirus Tagged Cancer Gene Database [65,66]. 
Very recently the advent of high throughput DNA sequencing has further increased the rate at 
which CISs can be identified. Host-viral junction fragments are PCR-amplified from tumor cells and 
then directly subjected to deep sequencing with the goal of identifying as many host cell insertion sites 
as possible. In a recent study, more than 9000 insertions from 476 lymphomas were identified [82]. Viruses 2011, 3                  
 
 
410
Data from retroviral tagging screens are now being compared with other cancer genome screens   
(e.g., comparative genomic hybridization) [111], providing a rich database for genetic changes in 
different cancers.  
Examination of CISs in MuLV-induced tumors has also suggested involvement of additional 
miRNAs in tumorigenesis. An informatic search of the RTCGD database identified 19 CISs that were 
within 10 Kb of an miRNA [112]. Some of these insertions could affect expression of an miRNA, 
similar to the activation of bic-1/miR155 in ALV-induced lymphomas.  
11. Insertional Mutagenesis and Gene Therapy 
Retrovirus-based vectors have been employed in human gene transfer experiments to introduce 
therapeutic molecules into cells to combat various diseases. The generation and use of retroviral 
vectors has been reviewed extensively [113]. Briefly, retroviral vectors are generated by recombinant 
DNA manipulations on plasmids containing a retroviral provirus. Internal viral coding sequences are 
substituted with DNA encoding a gene of interest; the viral LTRs and encapsidation (psi) signals for 
incorporation of viral RNA into particles are retained (Figure 4). Retroviral particles are obtained by 
introducing the vector DNA into “packaging” cells that express viral structural proteins from mRNAs 
that cannot themselves be packaged, or transiently co-transfecting cells with vector and helper 
plasmids. The transfected packaging cells will then produce viral particles that contain the vector 
sequences as RNA. These vector particles can then be used to infect target cells where reverse 
transcription and integration of the vector genome takes place, followed by expression of the vector. 
Retroviral vectors have the advantages that they integrate their DNA into the genomes of the infected 
host cells (transduction). Thus the genetic information for therapeutic molecules will permanently 
integrate into the target cells, which can lead to stable and prolonged expression. Retroviral vectors 
based on gammaretroviruses such as murine leukemia viruses were some of the first vectors employed 
in human gene transfer experiments, and they are still being used. More recently vectors based on 
lentiviruses such as HIV-1 have been employed [114].  
Figure 4. Retroviral vectors. Organization of a retroviral vector as well as two helper 
plasmids to produce the viral proteins are shown. Ψ, the packaging sequences on viral 
RNA. In some cases the helper plasmids are stably expressed in a packaging cell, or in 
other cases they are co-transfected with the vector plasmid.  
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The first human gene transfer trial used an MuLV-based vector expressing adenosine deaminase 
(ADA) for treatment of individuals with hereditary severe combined immuno-deficiency (SCID-ADA) 
that resulted from deficiency of ADA. The initial experiment involved ex vivo transduction of   
T-lymphocytes from the patients, followed by infusion of the transduced cells [115]. Transduced   
T-cells could be persistently detected in the patients receiving them, and there was evidence for 
clinical benefit—improvement of immunological status. Despite the theoretical concern that the 
transduced vectors might cause malignancies by insertional activation of proto-oncogenes, the two 
patients in the first trial did not show any evidence of malignancies. Subsequent trials to treat   
SCID-ADA have involved transduction of hematopoietic precursors (CD34+) ex vivo with   
ADA-expressing retroviral vectors; in total more than 30 patients have been treated worldwide, with 
correction of the immunodeficiency in many, and no malignancies [116].  
A watershed event for the gene therapy field occurred in clinical trials involving X-linked SCID—a 
genetic deficiency of the common gamma chain for growth factor receptors [117,118]. Hematopoietic 
progenitor cells (CD34+) from X-SCID patients (n = 20, results combined from two clinical trials in 
France and the UK) were transduced ex vivo with an MuLV-based vector expressing the common 
gamma chain and then infused into the patients. The transduced cells established and corrected the 
immunologic deficiency in 19 of 20 patients. However, five of the treated patients ultimately 
developed T-cell leukemia [119,120]. Analysis of the leukemic cells indicated that they shared a CIS at 
the cellular proto-oncogene LMO2 [121]. Additional integrations were observed at NOTCH1, 
CDKN2A, STIL-TAL1, CCND2 and BMI1 [120,122]. LMO2 had previously been found to be 
activated by chromosomal translocation in human T-cell leukemia [123]. In the X-SCID patients the 
MuLV LTR of the gene transfer vector was activating LMO2 expression. Thus the theoretical concern 
of insertional oncogenesis in gene transfer trails with retroviral vectors was confirmed. Recently a 
patient in an analogous trial to correct the genetic defect in Wiscott-Aldrich syndrome also developed a 
T-cell leukemia in which insertional activation of LMO2 was observed [124,125]. Likewise, a gene 
therapy trial using an MuLV-based vector to correct the genetic defect of X-linked chronic 
granulomatous disease resulted in myelodisplasia (a preleukemic syndrome) associated with 
insertional activation of the evi-1 proto-oncogene [126].  
Modifications of retroviral vectors to improve their safety have been developed, even before the 
complications in the X-SCID trial. One common modification is to remove the enhancer sequences 
from the U3 region of the LTR. This can be accomplished by deleting them from the U3 region of the 
downstream (but not upstream) LTR, of a plasmid containing a retroviral vector DNA. The U3 
sequences in the vector RNA will be derived from the downstream LTR, so after reverse transcription 
in an infected cell both LTRs will contain the deleted U3 regions and be inactive. Such vectors are 
referred to as self-inactivating (SIN) vectors [127]. Expression from SIN vectors is obtained by 
incorporating an internal promoter/enhancer. SIN vectors have the theoretical advantage that the 
deleted LTRs will not be able to insertionally activate proto-oncogenes. Additional modifications to 
retroviral vectors have included adding transcriptional insulator sequences to the LTRs or to the 
internal promoters [128]. Insulators prevent enhancers from activating promoters on the other side of 
an insulator.  
Lentivirus-based vectors are currently of considerable interest since they can infect non-dividing 
cells. Also lentiviruses (including HIV-1 and animal lentiviruses) do not induce tumors. In addition, Viruses 2011, 3                  
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while MuLV shows a preference for proviral insertion at or near start sites of transcription [129],  
HIV-1 shows a preference for inserting into the bodies of genes but not at their promoters [130]. The 
lack of integration specificity for transcriptional start sites might reduce the likelihood of insertional 
activation of proto-oncogenes by lentiviral vectors, although enhancer activation of proto-oncogenes 
can occur over several kilobases of DNA. Lentiviral SIN vectors have also been developed.  
Human gene transfer trials with lentiviral vectors are just beginning. One of the first trials has 
involved use of an HIV-based SIN vector expressing beta-globin to treat patients with beta-thalassemia 
[131]. In the first patient the vector was successful in correcting the beta-globin deficiency. However 
clonal dominance of a population of hematopoietic cells occurred in this patient, and the cells   
over-expressed HMGA2, a protein that is also over-expressed in cancers [132]. This could potentially 
indicate a pre-neoplastic state or cells with enhanced malignant potential, although there has been no 
progression to malignancy over 30 months. When the molecular mechanism for the over-expression of 
HMGA2 was investigated, it was found that the lentiviral vector was inserted downstream of HMGA2, 
which resulted in readthrough and splicing from HMGA2 mRNA into a cryptic splice acceptor site in a 
beta-globin insulator of the vector. This resulted in truncation of the HMGA2 mRNA and removal of 
the binding site for a regulatory miRNA which led to over-expression of HMGA2, analogous to 
activation of gfi-1 by SL3-3 MuLV (see Section 9). In fact lentiviral vectors might be more efficient at 
this mechanism, given their preference for inserting within the coding sequences of genes.  
The mechanisms of oncogenesis by non-acute animal retroviruses reviewed here provide useful 
perspectives for considering safety of retroviral vectors in human gene transfer experiments.   
Vector-associated malignancies have been observed in correction of three diseases so far, and 
monoclonal expansion has been observed in the ongoing beta-thalassemia trial. Mechanisms of   
proto-oncogene activation beyond enhancer/promoter activation need to be considered, and the relative 
frequencies of different mechanisms may differ for different vectors (gammaretroviral vs. lentiviral). 
The gene therapy field is relatively new, so most of the gene transfer experiments have been monitored 
for relatively short times. If insertional activation of proto-oncogenes contributes only one 
preneoplastic event, enhanced development of malignancies might take prolonged periods (decades) to 
become apparent. Indeed the latency of leukemia development by HTLV-I is decades. It may be 
impossible to completely eliminate the risk of insertional mutagenesis from retroviral vectors; the 
relative risks of oncogenesis need to be weighed against the benefits of the gene therapy   
(e.g., correction of SCID).  
12. Summary and Perspectives 
Studies of retroviruses that lack oncogenes (non-acute retroviruses) have provided important 
insights into oncogenesis. A common mechanism employed by these viruses is to insertionally activate 
cellular proto-oncogenes. A frequent process is LTR activation of proto-oncogenes, either by promoter 
insertion or enhancer activation. Study of different non-acute retroviruses has led to identification of 
new proto-oncogenes, and this has been accelerated by recent high throughput genomic studies. Study 
of retroviral oncogenesis in animals has highlighted the fact that oncogenesis is a multi-step process, 
and that proto-oncogene activation may provide only one or a few steps in this process. Alternate 
mechanisms of proto-oncogene activation besides LTR activation have also been observed, such as Viruses 2011, 3                  
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activation by truncation of regulatory domains in either the mRNA or protein. While no evidence for 
proto-oncogene activation has been observed for the well-characterized human pathogenic retroviruses 
(HTLV-I and HIV-1), these mechanisms will be important to consider when newly discovered 
potentially oncogenic human retroviruses are investigated. The mechanisms elucidated by study on 
non-acute retroviral oncogenesis in animal models also help to frame safety considerations for 
retroviral vectors in gene therapy trials.  
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